Yinzhi Lang

Yinzhi Lang, Ph.D.

Research Assistant Professor

Department: PH-DISTANCE CAMPUS-ORLANDO
Business Email: y.lang@ufl.edu

About Yinzhi Lang

Yinzhi Lang, PhD, is a Research Assistant Professor in the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy. Dr. Lang completed her PhD program in 2016 from Ocean University of China and worked as a senior Scientist in Shanghai Greenvalley Pharmaceutical Co.Ltd between 2016 and 2018. In 2018, Dr. Lang joined the College of Pharmacy at UF as a Postdoc and has received systematic training in antimicrobial pharmacology, pharmacokinetics and pharmacodynamics from Dr. Bulitta and his collaborators. In 2021, Dr. Lang was appointed as a Research Assistant Professor at UF. Her current research focus on elucidating the mechanisms of drug action and resistance via the latest mass spectrometry (MS)-based technology and Quantitative & Systems Pharmacology (QSP) modeling approach.

Dr. Lang has over 11 years of experience working with identification and quantification of biological endogenous molecules using liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based approaches. This includes the in-depth component and structural analysis of polysaccharides, oligosaccharides, glycoproteins, and glycolipids from marine algae, human milk, animal meat byproducts and microbial cells. For the pharmaceutical compounds, she has created a series of novel UPLC-MS/MS assays to quantify the target site penetration of various classes of antibiotics in Gram-negative bacteria and the intracellular accumulation of antiviral nucleosides/ nucleotides analogs in mammalian cells. Further, she has significantly contributed to the development of advanced QSP models, which can integrate the experimental mechanistic data with pathogen killing and resistance to rationally optimize anti-infective therapy. Moreover, she has extensive experience in pharmacokinetics and pharmacodynamics analysis of anti-infectives in in vitro and mouse infection models. Dr. Lang is leading and co-leading multiple federal funded anti-infective pharmacology research programs to create novel insights to combat serious infections.

Related Links:

Teaching Profile

Courses Taught
2023-2024
PHA6133 Translational Clinical Pharmacology

Board Certifications

  • National Computer Rank Examination (NCRE) (China)
    Visual C++ (Rank II) Certificate
  • National Computer Rank Examination (NCRE) (China)
    Internet technology (Rank III) Certificate

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-6857-4516

Areas of Interest
  • Bioanalysis
  • Infectious diseases
  • Pharmacokinetics/pharmacodynamics
  • Quantitative and Systems Pharmacology modeling
  • Translational and clinical pharmacology

Publications

2024
Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation.
Antimicrobial agents and chemotherapy. 68(3) [DOI] 10.1128/aac.01399-23. [PMID] 38329330.
2024
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard Inocula
Journal of Pharmaceutical Sciences. 113(1):202-213 [DOI] 10.1016/j.xphs.2023.10.029.
2024
Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics.
Antimicrobial agents and chemotherapy. 68(2) [DOI] 10.1128/aac.01393-23. [PMID] 38169309.
2024
Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae.
Scientific reports. 14(1) [DOI] 10.1038/s41598-024-53130-z. [PMID] 38326428.
2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
International Journal of Antimicrobial Agents. 63(6) [DOI] 10.1016/j.ijantimicag.2024.107161.
2023
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Antimicrobial agents and chemotherapy. 67(8) [DOI] 10.1128/aac.00414-23. [PMID] 37428034.
2023
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: resistance mechanisms and synergistic activity: Running title: Ceftolozane/tazobactam plus tobramycin against Pseudomonas biofilm.
International journal of antimicrobial agents. 62(3) [DOI] 10.1016/j.ijantimicag.2023.106887. [PMID] 37315906.
2023
Next generation beta-lactam combinations to combat persisters: Harnessing imipenem to curb carbapenem resistance in metallo-ß-lactamase-producing Klebsiella pneumoniae
mBio.
2023
Population Pharmacokinetics of Enrofloxacin and Florfenicol in the Giant Danio (Devario aequipinnatus) Following Oral and Bath Administration
Aquaculture.
2022
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Antibiotics (Basel, Switzerland). 11(1) [DOI] 10.3390/antibiotics11010101. [PMID] 35052977.
2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Antimicrobial agents and chemotherapy. 66(9) [DOI] 10.1128/aac.00527-22. [PMID] 35924913.
2022
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
Antimicrobial agents and chemotherapy. 66(3) [DOI] 10.1128/aac.02203-21. [PMID] 35041509.
2022
Why Molnupiravir Fails in Hospitalized Patients
mBio. 13(6) [DOI] 10.1128/mbio.02916-22. [PMID] 36374076.
2021
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Clinical pharmacology and therapeutics. 109(4):1000-1020 [DOI] 10.1002/cpt.2205. [PMID] 33576025.
2021
Comparison of Different Labeling Techniques for the LC-MS Profiling of Human Milk Oligosaccharides.
Frontiers in chemistry. 9 [DOI] 10.3389/fchem.2021.691299. [PMID] 34589467.
2021
Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy. 65(9) [DOI] 10.1128/AAC.00692-21. [PMID] 34152820.
2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrobial agents and chemotherapy. 65(1) [DOI] 10.1128/AAC.01956-20. [PMID] 33106266.
2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.
mBio. 11(1) [DOI] 10.1128/mBio.03189-19. [PMID] 32047131.
2018
Glycosaminoglycanomic profiling of human milk in different stages of lactation by liquid chromatography-tandem mass spectrometry.
Food chemistry. 258:231-236 [DOI] 10.1016/j.foodchem.2018.03.076. [PMID] 29655727.
2018
Separation and Structural Sequence Analysis of Sialylated HMOs via Tandem Mass Spectrometry
Chemical Journal of Chinese Universities. 39(4):645-652 [DOI] 10.7503/cjcu20170593.
2016
In Vivo Anti-Cancer Mechanism of Low-Molecular-Weight Fucosylated Chondroitin Sulfate (LFCS) from Sea Cucumber Cucumaria frondosa.
Molecules (Basel, Switzerland). 21(5) [DOI] 10.3390/molecules21050625. [PMID] 27187337.
2016
Isolation, Purification and Disaccharide Composition Analysis of Chondroitin Sulfate C from IRA Rabbit Lung
Chinese Journal of New Drugs. 25(10):1165-1169
2016
Isolation, purification and structural identification of glycosaminoglycans from porcine lung
Chinese Journal of Pharmaceutical Analysis. 36(4):587-593 [DOI] 10.16155/j.0254-1793.2016.04.05.
2016
Low anticoagulant heparin oligosaccharides as inhibitors of BACE-1, the Alzheimer’s β-secretase.
Carbohydrate polymers. 151:51-59 [DOI] 10.1016/j.carbpol.2016.05.050. [PMID] 27474542.
2015
Extraction, Isolation, Structural Characterization and Anti-Tumor Properties of an Apigalacturonan-Rich Polysaccharide from the Sea Grass Zostera caespitosa Miki.
Marine drugs. 13(6):3710-31 [DOI] 10.3390/md13063710. [PMID] 26110894.
2015
Isolation and Structural Identification of Neutral Human Milk Oligosaccharides
Chemical Journal of Chinese Universities. 36(6):1087-1093 [DOI] 10.7503/cjcu20150118.
2014
Applications of mass spectrometry to structural analysis of marine oligosaccharides.
Marine drugs. 12(7):4005-30 [DOI] 10.3390/md12074005. [PMID] 24983643.
2014
Isolation, purification and fine structure comparison analysis of glycosaminoglycans from three fish gills
Chinese Journal of Marine Drugs. 33(5):1-8 [DOI] 10.13400/j.cnki.cjmd.2014.05.001.
2014
Isolation, purification and physiochemical characteristics comparison study of polysaccharides between wild and low salinity cultured green seaweeds Chaetomorphalinum
Chinese Journal of Marine Drugs. 33(5):31-36 [DOI] 10.13400/j.cnki.cjmd.2014.05.005.
2014
Modification of reduction method about uronic acids in acidic polysaccharides
Chinese Journal of Marine Drugs. 33(4):1-7 [DOI] 10.13400/j.cnki.cjmd.2014.04.001.
2012
Analysis of structural heterogeneity of fucoidan from Hizikia fusiforme by ES-CID-MS/MS.
Carbohydrate polymers. 90(1):602-7 [DOI] 10.1016/j.carbpol.2012.05.084. [PMID] 24751082.

Grants

Aug 2024 ACTIVE
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2024 ACTIVE
Characterizing antibiotic efficacy via latest hollow fiber infection models and organs on a chip
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Dec 2023 – Jun 2024
Determination of receptor binding profiles and stability of novel drug candidates
Role: Co-Investigator
Funding: FEDORA PHARMACEUTICALS
Jan 2023 ACTIVE
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Dec 2022 ACTIVE
Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae
Role: Co-Investigator
Funding: UNIV OF ILLINOIS CHICAGO via NATL INST OF HLTH NIAID
Sep 2022 ACTIVE
Advancing In Vitro and (patho) Physiology-Based Pharmacokinetics Models to Understand and Predict Pulmonary Absorption and Tissue Retention of Inhaled Drugs
Role: Co-Investigator
Funding: US FOOD AND DRUG ADMN
Jul 2022 ACTIVE
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant staphylococci.
Role: Co-Investigator
Funding: PROKARYOTICS via NATL INST OF HLTH NIAID
Mar 2022 ACTIVE
Determination of tobramycin concentrations in plasma and tracheal aspirate of pediatric patients using latest LC-MS/MS
Role: Principal Investigator
Funding: CHILDRENS HOSP PHILADELPHIA via NATL INST OF HLTH NHLBI

Education

Ph.D.
2011-2016 · Ocean University of China
B.S.
2007-2011 · Yantai University

Contact Details

Emails:
Business:
y.lang@ufl.edu
Addresses:
Business Mailing:
6550 SANGER RD OFC 145
ORLANDO FL 32827
Business Street:
6550 SANGER RD
ORLANDO FL 32827